Isotretinoin

Nonpregnant patients ≥ 12 with severe recalcitrant nodular acne and multiple inflammatory nodules ≥ 5 mm, unresponsive to conventional therapy including systemic antibiotics. This profile gives the selected FDA-labeled indication, not a blanket regimen for milder acne or all off-label retinoid uses.

A usual course is 15–20 weeks. Improvement may continue after stopping; wait at least 2 months before considering another course. Retreatment directions concern completed skeletal growth; optimal interval in those still growing is not defined. Long-term low-dose use has not been studied and is not recommended by these selected labels.

Individualize response and tolerability; totals below are per day, divided into two doses, usually for 15–20 weeks. Conventional selected capsules: 0.5–1 mg/kg/day with food. Absorica: 0.5–1 mg/kg/day with or without food. Absorica LD: 0.4–0.8 mg/kg/day with or without food. Adults with very severe scarring/truncal disease may need up to 2 mg/kg/day conventional/Absorica or 1.6 mg/kg/day LD, divided as tolerated; these adult escalation limits are not universal pediatric starts. Once-daily dosing is not recommended.

Swallow capsules whole with a full glass of liquid; do not split, crush, chew or suck. Select available intact strengths rather than an invented home preparation. Skip a missed dose and never double. Adjust to clinical response/adverse reactions; the labels permit stopping before 15–20 weeks if nodules have improved > 70%. No mandatory universal cumulative-mg target or unsupervised repeat course is supplied.

Confirm pregnancy status when relevant, fasting lipids and LFTs before therapy. All patients enroll in iPLEDGE with certified prescriber/pharmacy. For patients who can become pregnant, negative testing is required for each prescription; the label describes a 7-day pickup window measured from specimen collection. Prescriptions are for no more than 30 days without refills. Confirm current program authorization rather than infer transition-system changes from a newer PI alone.

FDA delayed implementation of its February 2026 iPLEDGE modifications until November 15, 2026. Until implemented, the October 2023 testing enforcement discretion continues: pretreatment tests remain in a medical setting; a prescriber may permit/document home tests during and after treatment. Future administrative changes must not be described as already active. Confirm the live program’s authorization rules and current FDA update at dispensing.

Pregnancy, and hypersensitivity to isotretinoin, vitamin A or the exact product’s ingredients. REMS controls, lactation advice and severe systemic precautions require additional assessment but are not interchangeable with the formal contraindication list.

Both selected current labels have an embryo-fetal-toxicity boxed warning: isotretinoin is contraindicated in pregnancy and is available only through the restricted iPLEDGE REMS. Any amount, even short exposure, may cause severe fetal harm; pregnancy must be prevented during treatment and for 1 month after.

Common clinical effects include dry/chapped lips, dry skin/eyes, epistaxis, headache, back/joint pain and lipid/liver-test changes. Serious reported effects span psychiatric, neurologic, GI, blood, bone/muscle, ocular, hearing and allergic disorders; voluntary reports cannot establish frequency/causality, including whether every IBD report was drug-caused. Sexual dysfunction may persist in some reports. Overdose needs medical/Poison Help evaluation and pregnancy assessment when relevant; do not donate blood for at least 1 month. After overdose, men should use condoms or avoid reproductive sex with someone pregnant or potentially pregnant for 1 month because semen exposure may be higher.

Avoid vitamin A supplements and tetracyclines. The studied norethindrone/ethinyl-estradiol contraceptive showed no clinically significant PK change; other oral contraceptive interactions remain uncertain. This does not remove two-method/abstinence requirements. Review medicines/herbals that impair contraception, and all bone-risk co-therapy. Microdosed progestin-only minipills are inadequate for the REMS contraception plan; not every progestin implant/injection is excluded.

For patients who can become pregnant: two pretreatment medical-setting tests, screening then confirmation at least 30 days later; confirm after 1 month using two accepted methods or continuous abstinence. With regular cycles, confirm in the first 5 menstrual days immediately before starting; other-cycle circumstances have product-specific timing. Test before every prescription, at course end and 1 month after. Use two accepted methods with at least one primary for 1 month before, throughout and 1 month after, unless a qualifying exception/continuous abstinence applies. After unprotected potentially reproductive sex, stop if on therapy and contact the prescriber; labels require a test ≥ 19 days after that encounter, a month of the prevention plan before restart and another test. That exposure-test interval is distinct from the future administrative “19-day lockout” change.

Pregnancy is contraindicated. Report exposure promptly to the prescriber, FDA and iPLEDGE, and obtain specialist counseling; absence of an early symptom does not exclude fetal harm. Breastfeeding is not recommended during therapy or for at least 8 days after the last dose because serious infant reactions are possible and milk/infant data are unavailable. This shorter lactation interval does not shorten the 1-month pregnancy-prevention or blood-donation restriction.

Labeled severe recalcitrant nodular acne use is established from 12; below 12 is unestablished. Back/joint pain can be more frequent in children, and BMD decline/premature epiphyseal closure are reported; assess musculoskeletal symptoms and growth context. Geriatric trials were insufficient to establish differential response, and aging may increase some risks.

The selected PIs supply no fixed renal/hepatic dose-adjustment algorithm. Check LFTs before and periodically during therapy; discontinue if abnormalities do not normalize readily or hepatitis is suspected. Organ disease, metabolic risks and co-therapy require specialist selection, not an invented eGFR percentage reduction.

Exact therapeutic mechanism is not fully known; reduced sebaceous-gland activity/size and sebum secretion accompany benefit. Protein binding > 99.9%; metabolism involves CYP2C8, 2C9, 3A4 and 2B6 and active-in-vitro retinoid metabolites. Conventional fed adult study: peak about 5.3 hours, isotretinoin half-life about 21 hours; a high-fat meal increased exposure about 2.7-fold versus fasting. Absorica fed peak about 6.4 hours/half-life 18 hours; LD fed median peak 5 hours/half-life 24 hours in different single-dose studies. These are formulation/study values, not head-to-head equivalence; Absorica/LD can be taken without food. Radiolabeled metabolites are recovered in urine/feces.

Baseline and follow-up pregnancy tests per clinical/REMS plan; fasting lipids and LFTs periodically until response is known, with closer follow-up for diabetes, obesity, heavy alcohol or lipid-disorder risk. Labels advise waiting 36 hours after alcohol before lipid testing. Assess mood/suicidality at each visit, skin/GI/hearing/vision and musculoskeletal symptoms; glucose/CPK tests are context-dependent rather than mandatory universal panels. Uncontrolled triglycerides or suspected hepatitis/pancreatitis require stopping/evaluation.

Use only your exact prescribed formulation; conventional capsules need food, whereas Absorica/LD do not. Never share, double or donate blood during/for 1 month after treatment. Follow testing/contraception, and promptly report pregnancy or unprotected sex. Avoid vitamin A/tetracyclines; discuss alcohol and intense exercise. Use sun protection and soothing care for dryness; avoid waxing/abrasive skin procedures/laser resurfacing during and for at least 6 months after because of scarring risk. Take new mood, vision, hearing, severe rash or abdominal symptoms seriously and contact the team promptly.

Absorica 20 mg opaque red capsule, G 241 / 20; NDC10631-116-31, 30-capsule prescription-pack carton. Verify the package and iPLEDGE authorization; this identity is not evidence of local stock or interchangeability with LD 20 mg.

Selected conventional capsules: 10, 20, 30 and 40 mg, current ANDA211568 Prescription. Absorica: 10, 20, 25, 30, 35 and 40 mg, NDA021951 Prescription. Absorica LD PI lists 8, 16, 20, 24, 28 and 32 mg; current FDA NDA211913 lists 8, 16, 24 and 32 mg Prescription but 20 and 28 mg Discontinued. Retain that status distinction even though the shared PI still describes all strengths. No mg-for-mg exchange between conventional, Absorica and LD is implied.

Store 20–25°C, excursions 15–30°C, protect from light and retain the prescribed package. Never remove capsules to create an unverified home liquid or strength. Keep away from children and others; dispense only under the current REMS authorization and with the Medication Guide.